Trichomonas vaginalis Antimicrobial Drug Resistance in 6 US Cities, STD Surveillance Network, 2009–2010
Robert D. Kirkcaldy , Peter Augostini, Lenore E. Asbel, Kyle T. Bernstein, Roxanne P. Kerani, Christie J. Mettenbrink, Preeti Pathela, Jane R. Schwebke, W. Evan Secor, Kimberly A. Workowski, Darlene Davis, Jim Braxton, and Hillard S. Weinstock
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (R.D. Kirkcaldy, P. Augostini, W.E. Secor, K.A. Workowski, D. Davis, J. Braxton, H.S. Weinstock); Philadelphia Department of Public Health, Philadelphia, Pennsylvania, USA (L.E. Asbel),; San Francisco Department of Public Health, San Francisco, California, USA (K.T. Bernstein); Public Health–Seattle and King County, Seattle, Washington, USA (R.P. Kerani); Denver Public Health Department, Denver, Colorado, USA (C. Mettenbrink); New York City Department of Health and Mental Health, New York, New York, USA (P. Pathela); Jefferson County Department of Health, Birmingham, Alabama, USA (J.R. Schwebke); University of Alabama, Birmingham (J.R. Schwebke); Emory University, Atlanta (K.A. Workowski)
Figure. . . Distribution of minimum lethal concentrations (MLCs) of tinidazole and metronidazole, STD Surveillance Network, 2009–2010 (n = 538). Susceptibility to metronidazole and tinidazole are defined as MLC <25 μg/mL, low-level resistance as MLC 50–100 μg/mL, moderate-level resistance as MLC 200 μg/mL, and high-level resistance as MLC >400 μg/mL.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.